Local Institution
Montreal, Quebec, H2W1R7, Canada
NCT Number: NCT00847782
The purpose of this study is to validate novel assays for serum biomarkers of lipid metabolism (PCSK9 and LDL receptor) and to obtain information about how these biomarkers differ in subjects with normal or high cholesterol levels
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Montreal, Quebec, H2W1R7, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 day
Time frame: Initial assessment will occur when Group 1 has 50 subjects enrolled and Groups 2 and 3 have 30 subjects enrolled
Time frame: Initial assessment will occur when Groups 2 and 3 have enrolled 30 subjects
Time frame: Initial assessment will occur when Groups 2 and 3 have enrolled 30 subjects
Time frame: Initial assessment will occur when Groups 2 and 3 have enrolled 30 subjects
Time frame: Initial assessment will occur when Groups 2 and 3 have enrolled 30 subjects
Bristol-Myers Squibb
Industry
An Experimental Medicine Study to Quantify PCSK9 Serum Concentrations and LDL Receptor Expression in Peripheral Blood Cells in Normal and Hypercholesterolemic Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05906797
Arterial Occlusive Diseases, Arteriosclerosis
Catania, Italy
View Trial DetailsNCT02991703
Arterial Occlusive Diseases, Arteriosclerosis
Nantes, France
View Trial DetailsNCT04167761
Arterial Occlusive Diseases, Arteriosclerosis
Stanford, California, United States
View Trial DetailsNCT02505399
Arterial Occlusive Diseases, Arteriosclerosis
Toulouse, Haute-Garonne, France
View Trial Details